Claire M Edwards

Summary

Affiliation: Vanderbilt University
Country: USA

Publications

  1. pmc A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease
    Bruce P Ayati
    Department of Mathematics, University of Iowa, Iowa City, IA 52242, USA
    Biol Direct 5:28. 2010
  2. pmc Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
    Claire M Edwards
    Department of Cancer Biology, Vanderbilt Center for Bone Biology, Vanderbilt University, Nashville, TN 37232, USA
    Blood 111:2833-42. 2008
  3. pmc The pathogenesis of the bone disease of multiple myeloma
    Claire M Edwards
    Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA
    Bone 42:1007-13. 2008
  4. pmc Eph receptors and ephrin signaling pathways: a role in bone homeostasis
    Claire M Edwards
    Vanderbilt Center for Bone Biology, Departments of Cancer Biology and Clinical Pharmacology Medicine, Vanderbilt University, Nashville, TN 37232 0575, USA
    Int J Med Sci 5:263-72. 2008
  5. pmc Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo
    Claire M Edwards
    Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, 1235 Medical Research Building IV, Nashville, TN 37232 0575, USA
    Am J Hematol 84:268-72. 2009
  6. pmc Tumor-host cell interactions in the bone disease of myeloma
    Jessica A Fowler
    Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA
    Bone 48:121-8. 2011
  7. pmc Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells
    Junling Zhuang
    Department of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
    PLoS ONE 7:e48871. 2012
  8. pmc Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease
    Jessica A Fowler
    Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA
    Blood 118:5872-82. 2011
  9. pmc Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1
    Jessica A Fowler
    Department of Cancer Biology, Vanderbilt Center for Bone Biology, Vanderbilt University, Nashville, Tennessee, USA
    Cancer Res 72:2183-9. 2012
  10. pmc A murine model of myeloma that allows genetic manipulation of the host microenvironment
    Jessica A Fowler
    Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA
    Dis Model Mech 2:604-11. 2009

Collaborators

Detail Information

Publications14

  1. pmc A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease
    Bruce P Ayati
    Department of Mathematics, University of Iowa, Iowa City, IA 52242, USA
    Biol Direct 5:28. 2010
    ..Multiple myeloma is a hematologic malignancy associated with the development of a destructive osteolytic bone disease...
  2. pmc Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo
    Claire M Edwards
    Department of Cancer Biology, Vanderbilt Center for Bone Biology, Vanderbilt University, Nashville, TN 37232, USA
    Blood 111:2833-42. 2008
    ....
  3. pmc The pathogenesis of the bone disease of multiple myeloma
    Claire M Edwards
    Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, Tennessee, USA
    Bone 42:1007-13. 2008
    ..This review discusses the many different factors which have been implicated in myeloma bone disease, including the evidence for their role in myeloma and subsequent therapeutic implications...
  4. pmc Eph receptors and ephrin signaling pathways: a role in bone homeostasis
    Claire M Edwards
    Vanderbilt Center for Bone Biology, Departments of Cancer Biology and Clinical Pharmacology Medicine, Vanderbilt University, Nashville, TN 37232 0575, USA
    Int J Med Sci 5:263-72. 2008
    ....
  5. pmc Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo
    Claire M Edwards
    Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, 1235 Medical Research Building IV, Nashville, TN 37232 0575, USA
    Am J Hematol 84:268-72. 2009
    ..Our results demonstrate that myeloma cells exhibit an increase in proteasome activity and an enhanced response to bortezomib treatment when located within the bone marrow microenvironment in vivo...
  6. pmc Tumor-host cell interactions in the bone disease of myeloma
    Jessica A Fowler
    Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA
    Bone 48:121-8. 2011
    ..This review discusses the cellular mechanisms and potential therapeutic targets that have been implicated in myeloma bone disease...
  7. pmc Osteoclasts in multiple myeloma are derived from Gr-1+CD11b+myeloid-derived suppressor cells
    Junling Zhuang
    Department of Medicine and Pharmacology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America
    PLoS ONE 7:e48871. 2012
    ..Collectively, these data provide in vitro and in vivo evidence that tumor-induced MDSCs exacerbate cancer-associated bone destruction by directly serving as osteoclast precursors...
  8. pmc Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease
    Jessica A Fowler
    Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, TN, USA
    Blood 118:5872-82. 2011
    ..Furthermore, we have established the potential therapeutic benefit of increasing adiponectin for the treatment of myeloma and the associated bone disease...
  9. pmc Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1
    Jessica A Fowler
    Department of Cancer Biology, Vanderbilt Center for Bone Biology, Vanderbilt University, Nashville, Tennessee, USA
    Cancer Res 72:2183-9. 2012
    ..Collectively, our results show novel roles of BMSCs and BMSC-derived Dkk1 in the pathogenesis of multiple myeloma in vivo...
  10. pmc A murine model of myeloma that allows genetic manipulation of the host microenvironment
    Jessica A Fowler
    Vanderbilt Center for Bone Biology, Department of Cancer Biology, Vanderbilt University, Nashville, TN 37232, USA
    Dis Model Mech 2:604-11. 2009
    ..The establishment of myeloma in RAG-2(-/-) mice permits molecular examination of the host contribution to myeloma pathogenesis in vivo...
  11. pmc Gr-1+CD11b+ myeloid-derived suppressor cells: formidable partners in tumor metastasis
    Li Yang
    Department of Cancer Biology, Vanderbilt University Medical Center, Nashville, TN, USA
    J Bone Miner Res 25:1701-6. 2010
    ..They also have a potential role in the osteolysis associated with bone metastases. They are formidable partners in tumor metastasis...
  12. ncbi request reprint Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo
    Claire M Edwards
    Institute of Musculoskeletal Sciences and the Nuffield Department of Orthopaedic Surgery, University of Oxford, Nuffield Orthopaedic Center, Oxford, United Kingdom
    Int J Cancer 120:1657-63. 2007
    ..The use of bisphosphonate esters such as Apomine represents a novel therapeutic approach in the treatment of myeloma and, indirectly, the associated bone disease...
  13. pmc Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis
    Rachel M Locklin
    Institute of Musculoskeletal Sciences, Botnar Research Centre, Nuffield Department of Orthopaedic Surgery, University of Oxford, Oxford OX3 7LD, United Kingdom
    Mol Cancer Ther 6:3219-28. 2007
    ....
  14. pmc Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase
    Anke J Roelofs
    Bone Research Group, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, UK
    J Pharmacol Exp Ther 322:228-35. 2007
    ..Thus, these findings demonstrate a novel strategy for enhancing the antitumor effects of lovastatin...